

CLAIMS

1. A composition comprising
130 mg/ml to 170 mg/ml of an anti-IL-33 IgG1 antibody,
190 mM to 250 mM arginine,
polysorbate 80 at a concentration of 0.005% (w/v) to 0.05% (w/v),
a buffer, wherein the buffer is histidine, and
a pH of pH 5.0 to pH 6.0,
wherein the anti-IL-33 antibody comprises:
 - i. a heavy chain variable domain comprising a VHCDR1 having the sequence of SEQ ID NO: 1, a VHCDR2 having the sequence of SEQ ID NO: 2, a VHCDR3 having the sequence of SEQ ID NO: 3; and
 - ii. a light chain variable domain comprising a VLCDR1 having the sequence of SEQ ID NO: 5, a VLCDR2 having the sequence of SEQ ID NO: 6, and a VLCDR3 having the sequence of SEQ ID NO: 7.
2. The composition of claim 1, wherein the anti-IL-33 antibody comprises:
 - (a) a heavy chain variable domain that is:
 - i. a sequence of amino acids that is at least 95%, 90%, 85% or 80% identical to SEQ ID NO: 4; or
 - ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO: 11;
 - (b) a light chain variable domain that is:
 - i. a sequence of amino acids that is at least 95%, 90%, 85% or 80% identical to SEQ ID NO: 8; or
 - ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO: 12; or
 - (c) a heavy chain variable domain of (a) and a light chain variable domain of (b).
3. The composition of any one of the preceding claims, wherein the anti-IL-33 antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 4, a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 8, or a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 4 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 8.

4. The composition of any one of the preceding claims, wherein the anti-IL-33 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:9, a light chain comprising the amino acid sequence of SEQ ID NO:10, or a heavy chain comprising the amino acid sequence of SEQ ID NO:9 and a light chain comprising the amino acid sequence of SEQ ID NO:10.
5. The composition of any one of the preceding claims, wherein the anti-IL-33 antibody is present at a concentration of 150 mg/ml $\pm$ 10%.
6. The composition of any one of the preceding claims, comprising 0.03% (w/v) $\pm$ 0.010% (w/v) polysorbate 80.
7. The composition of any one of the preceding claims, comprising 220 mM arginine.
8. The composition of any one of the preceding claim, wherein the arginine is L-arginine hydrochloride.
9. The composition of any one of the preceding claims, wherein the buffer is L-histidine/L-histidine hydrochloride.
10. The composition of any one of the preceding claims, wherein the buffer is at a concentration of 19 mM to 21 mM, optionally 20 mM $\pm$ 10% buffer.
11. The composition of any one of the preceding claims, which is a liquid.
12. The composition of any one of the preceding claims, wherein the pH is about pH 5.5.
13. The composition of claim 11 or 12, characterized by the anti-IL-33 antibody having reduced reversible self-association relative to the reversible self-association of the anti-IL-33 antibody in a composition comprising 20 mM histidine, 80 mM arginine, 120 mM sucrose, 0.02% (w/v) polysorbate 80 at pH 6.0 and a lower concentration of the anti-IL-33 antibody, for example 50 mg/ml.
14. A composition comprising 130 mg/ml to 170 mg/ml 33_640087-7B, about 0.03% (w/v) $\pm$ 0.015% polysorbate 80, about 220 mM arginine, and 16 to 24 mM histidine buffer, wherein the pH is pH 5.5 $\pm$ 0.5, wherein 33_640087-7B is an anti-IL-33 IgG1 antibody

having a heavy chain amino acid sequence of SEQ ID NO:9 and a light chain amino acid sequence of SEQ ID NO:10.

15. A composition comprising 150 mg/ml 33_640087-7B, 20 mM His/His-HCl, 220 mM Arg-HCl, 0.03% (w/v) polysorbate 80, wherein the pH is pH 5.5, wherein 33_640087-7B is an anti-IL-33 IgG1 antibody having a heavy chain amino acid sequence of SEQ ID NO:9 and a light chain amino acid sequence of SEQ ID NO:10.
16. An article of manufacture, comprising the composition of any one of the preceding claims, optionally comprising 0.5 ml to 5 ml (e.g., 1 ml to 3 ml) of the composition.
17. A vial comprising the composition of any one of claims 1 to 15, optionally comprising 0.5 ml to 5 ml (e.g., 1 ml to 3 ml) of the composition.
18. A composition of any one of claims 1 to 15 for use in therapy.
19. The composition for use of claim 18, wherein the composition is for use in a method of treating an IL-33-mediated disorder, wherein the IL-33-mediated disorder is asthma.